A Study of LY3832479 (LY-CoV016) in Healthy Participants

NCT04441931 ↗

Phase 1 Completed 26 enrolled Eli Lilly and Company

RandomizedSequentialDouble-blindBasic science

Summary

The main purpose of this study is to learn more about the safety of LY3832479 and any side effects that might be associated with it. Blood tests will be done to measure how much LY3832479 is in the bloodstream and how long it takes the body to eliminate it. Participation could last up to 16 weeks and may include up to 10 visits to the study center.

Timeline

Start: 2020-06-19
Primary completion: 2020-10-02
Completion: 2020-10-02

Publications

Kreuzberger N, Hirsch C, Chai KL, Tomlinson E, Khosravi Z, Popp M, Neidhardt M, Piechotta V, Salomon S, Valk SJ, Monsef I, Schmaderer C, Wood EM, So-Osman C, Roberts DJ, McQuilten Z, Estcourt LJ, Skoetz N. SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19. Cochrane Database Syst Rev. 2021 Sep 2;9(9):CD013825. doi: 10.1002/14651858.CD013825.pub2.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Etesevimab	Monoclonal antibody	700 mg	Intravenous
Subject	Etesevimab	Monoclonal antibody	2800 mg	Intravenous
Subject	Etesevimab	Monoclonal antibody	7000 mg	Intravenous

Indications

No indication recorded.